Chief Executive Officer Que Dallara credited the strong start to robust execution across the company’s innovation pipeline and a successful strategy for patient acquisition. The U.S. launch of the MiniMed Flex™ platform is performing as intended, driving competitive conversions and expanding the company's total footprint. Globally, the firm maintained momentum with 18% reported growth in international markets, fueled by increased capacity for Simplera™ and the deployment of the Instinct sensor.

Operational milestones hit during the quarter include the FDA submission of the MiniMed Fit™ patch pump and the receipt of a CE Mark for the MiniMed Flex™ device. Looking ahead, MiniMed has raised its full-year organic revenue growth guidance to approximately 10.5%. The company remains focused on its fully-closed loop Vivera™ algorithm, with a pivotal U.S. trial now complete and a commercial launch projected for the second half of 2027.